Tumor Biology

, Volume 37, Issue 7, pp 9263–9271 | Cite as

Correlation of Cyfra 21-1 levels in saliva and serum with CK19 mRNA expression in oral squamous cell carcinoma

  • Rewa Malhotra
  • Aadithya B. Urs
  • Anita Chakravarti
  • Suman Kumar
  • V. K. Gupta
  • Bhawna Mahajan
Original Article

Abstract

Oral squamous cell carcinoma (OSCC) accounts for 90 % of malignant lesions of oral cavity. The study assessed the potential of Cyfra 21-1 as a tumor marker in OSCC. The study included 50 patients of OSCC to evaluate levels of Cyfra 21-1 in serum and saliva by electrochemiluminescent immunoassay (ECLIA) and CK19 messenger RNA (mRNA) expression in tissue by florescent quantitative real-time reverse transcriptase polymerase chain reaction (RT-PCR) along with healthy individuals as control. The salivary and serum Cyfra 21-1 levels in patients of OSCC were significantly higher compared to controls (p value < 0.01). There was a 2.75-fold increase in CK19 mRNA expression in OSCC cases compared to controls. A significant positive correlation was found between serum and salivary Cyfra 21-1, serum Cyfra 21-1, and CK19 mRNA expression and between salivary Cyfra 21-1 and CK19 mRNA expression. Among these, correlation between serum and salivary Cyfra 21-1 was highly significant. Salivary and serum Cyfra 21-1 showed significantly elevated levels in grade II OSCC compared to grade I histopathologically. Elevated levels of salivary Cyfra 21-1 were associated with recurrence in OSCC patients. Reverse operating curve constructed using 3 ng/ml as a cutoff for serum Cyfra 21-1 revealed the sensitivity and specificity to be 88 and 78.2 %, respectively. Using a cutoff value of 8.5 ng/ml for salivary Cyfra 21-1, the sensitivity was found to be 93.8 % and specificity 84.3 %. We advocate salivary Cyfra 21-1 as a better diagnostic marker over serum Cyfra 21-1 as well as a potential marker in the prognosis of OSCC.

Keywords

Cyfra 21-1 Oral squamous cell carcinoma Cytokeratin19 Electrochemiluminescent immunoassay Polymerase chain reaction 

Notes

Compliance with ethical standards

Ethics approval and consent to participate

The study protocol was approved by the Institutional Ethical Board Committee as a part of the research activities of the institute. Informed consent was taken from every patient participating in the study.

References

  1. 1.
    American Cancer Society. Cancer Facts and Figures 2007. Atlanta: American Cancer Society 2007.Google Scholar
  2. 2.
    Warnakulasuriya S. Global epidemiology of oral and oropharyngeal cancer. Oral Oncol. 2009;45:309–16.CrossRefPubMedGoogle Scholar
  3. 3.
    Markopoulos AK, Michailidou EZ, Tzimagiorgis G. Salivary markers for oral cancer detection. Open Dent J. 2010;4:172–8.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Zhong LP, Zhang CP, Zheng JW, Li J, Chen WT, Zhang ZY. Increased Cyfra 21-1 concentration in saliva from primary oral squamous cell carcinoma patients. Arch Oral Biol. 2007;52:1079–87.CrossRefPubMedGoogle Scholar
  5. 5.
    Doweck I, Barak M, Uri N, Greenberg E. The prognostic value of the tumour marker Cyfra 21-1 in carcinoma of head and neck and its role in early detection of recurrent disease. Br J Cancer. 2000;83:1696–701.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Moll R, Franke WW, Schiller DL, Geiger B, Krepler R. The catalog of human cytokeratins: patterns of expression in normal epithelia, tumors and cultured cells. Cell. 1982;31:11–24.CrossRefPubMedGoogle Scholar
  7. 7.
    Sawant SS, Zingde SM, Vaidya MM. Cytokeratin fragments in the serum: their utility for the management of oral cancer. Oral Oncol. 2008;44:722–32.CrossRefPubMedGoogle Scholar
  8. 8.
    Barak V, Goike H, Panaretakis KW, Einarsson R. Clinical utility of cytokeratins as tumor markers. Clin Biochem. 2004;37:529–40.CrossRefPubMedGoogle Scholar
  9. 9.
    Broers JL, Ramaekers FC, Rot MK, Oostendorp T, Huysmans A, van Muijen GN, et al. Cytokeratins in different types of human lung cancer as monitored by chain-specific monoclonal antibodies. Cancer Res. 1988;48:3221–9.PubMedGoogle Scholar
  10. 10.
    Bodenmuller H, Ofenloch-Hahnle B, Lane EB, Dessauer A, Bottger V, Donie F. Lung cancer-associated keratin 19 fragments: development and biochemical characterisation of the new serum assay Enzymun-Test CYFRA 21-1. Int J Biol Markers. 1994;9:75–81.PubMedGoogle Scholar
  11. 11.
    Dohmoto K, Hojo S, Fujita J, Yang Y, Ueda Y, Bandoh S, et al. The role of caspase 3 in producing cytokeratin 19 fragment (CYFRA 21-1) in human lung cancer cell lines. Int J Cancer. 2001;91:468–73.CrossRefPubMedGoogle Scholar
  12. 12.
    Sheard MA, Vojtesek B, Simickova M, Valik D. Release of cytokeratin-18 and -19 fragments (TPS and CYFRA 21-1) into the extracellular space during apoptosis. J Cell Biochem. 2002;85:670–7.CrossRefPubMedGoogle Scholar
  13. 13.
    Satyam A, Singh P, Sharma M, Seth A, Sharma A. CYFRA 21-1: a potential molecular marker for noninvasive differential diagnosis of urothelial carcinoma of bladder. Biomarkers. 2011;16:413–21.CrossRefPubMedGoogle Scholar
  14. 14.
    Cheng B, Rhodus NL, Williams B, Griffin RJ. Detection of apoptotic cells in whole saliva of patients with oral premalignant and malignant lesions: a preliminary study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2004;97:465–70.CrossRefPubMedGoogle Scholar
  15. 15.
    Wong DT. Salivary diagnostics powered by nanotechnologies, proteomics and genomics. J Am Dent Assoc. 2006;137:313–21.CrossRefPubMedGoogle Scholar
  16. 16.
    Vora HH, Shah NG, Patel DD, Trivedi TI, Chikhlikar PR. Prognostic significance of biomarkers in squamous cell carcinoma of the tongue: multivariate analysis. J Surg Oncol. 2003;82:34–50.CrossRefPubMedGoogle Scholar
  17. 17.
    Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A, eds. AJCC Cancer Staging Manual, 7th ed. New York: Springer, 2010:29–35.Google Scholar
  18. 18.
    Anneroth G, Batsakis J, Luna M. Review of literature and recommended system of malignancy grading in oral squamous cell carcinoma. Scand J Dent Res. 1987;95:229–49.PubMedGoogle Scholar
  19. 19.
    Akhter M, Hossain S, Rahman QB, Molla MR. A study on histological grading of oral squamous cell carcinoma and its co-relationship with regional metastasis. J Oral Maxillofac Pathol. 2011;15:168–76.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Doshi NP, Shah SA, Patel KB, Jhabuawala MF. Histological grading of oral cancer: a comparison of different systems and their relation to lymph node metastasis. Ntnl J Comm Med. 2011;2:136–42.Google Scholar
  21. 21.
    Céruse P, Rabilloud M, Charrié A, Dubreuil C, Disant F. Study of cyfra 21-1, a tumor marker, in head and neck squamous cell carcinoma. Ann Otol Rhinol Laryngol. 2005;114:768–76.CrossRefPubMedGoogle Scholar
  22. 22.
    Pujol JL, Grenier J, Daures JP, Daver A, Pujol H, Michel FB. Serum fragment of cytokeratin subunit 19 measured by Cyfra 21-1 immunoradiometric assay as a marker of lung cancer. Cancer Res. 1993;53:61–6.PubMedGoogle Scholar
  23. 23.
    Gadducci A, Ferdeghini M, Cosio S, Fanucchi A, Cristofani R, Genazzani AR. The clinical relevance of serum CYFRA 21-1 assay in patients with ovarian cancer. Int J Gynecol Cancer. 2001;11:277–82.CrossRefPubMedGoogle Scholar
  24. 24.
    Al-Shagahin H, Alkotyfan K, Müller HH, Sesterhenn AM, Werner JA. Cyfra 21-1 as a serum tumor marker for follow-up of patients with laryngeal and hypopharyngeal squamous cell carcinoma. Anticancer Res. 2009;29:3421–5.PubMedGoogle Scholar
  25. 25.
    Deng YF, Chen P, Lin YZ, Le JZ, Wu XL, Yu MQ, et al. Analytical and clinical evaluation of CYFRA 21-1 by electrochemiluminescent immunoassay in head and neck squamous cell carcinoma. J Laryngol Otol. 2003;117:190–4.PubMedGoogle Scholar
  26. 26.
    Doweck I, Barak M, Greenberg E, Uri N, Kellner J, Lurie M, et al. Cyfra 21-1: a new potential tumor marker for squamous cell carcinoma of head and neck. Arch Otolaryngol Head Neck Surg. 1995;121:177–81.CrossRefPubMedGoogle Scholar
  27. 27.
    Zhong LP, Zhu HG, Zhang CP, Chen WT, Zhang ZY. Detection of serum Cyfra 21-1 in patients with primary oral squamous cell carcinoma. Int J OralMaxillofac Surg. 2007;36:230–4.CrossRefGoogle Scholar
  28. 28.
    Yen TC, Lin WY, Kao CH, Cheng KY, Wang SJ. A study of a new tumour marker, CYFRA 21-1, in squamous cell carcinoma of the head and neck, and comparison with squamous cell carcinoma antigen. Clin Otolaryngol Allied Sci. 1998;23:82–6.CrossRefPubMedGoogle Scholar
  29. 29.
    Nagler R, Bahar G, Shpitzer T, Feinmesser R. Concomitant analysis of salivary tumor markers – a new diagnostic tool for oral cancer. Clin Cancer Res. 2006;12:3979–84.CrossRefPubMedGoogle Scholar
  30. 30.
    Rajkumar K, Ramya R, Nandhini G, Rajashree P, Ramesh Kumar A, Nirmala AS. Salivary and serum level of CYFRA 21-1 in oral precancer and oral squamous cell carcinoma. Oral Dis. 2015;21:90–6.CrossRefPubMedGoogle Scholar
  31. 31.
    Sánchez-Carbayo M, Espasa A, Chinchilla V, Herrero E, Megías J, Mira A. New electrochemiluminescent immunoassay for the determination of CYFRA 21-1: analytical evaluation and clinical diagnostic performance in urine samples of patients with bladder cancer. Clin Chem. 1999;45:1944–53.PubMedGoogle Scholar
  32. 32.
    Zhong LP, Zhao SF, Chen GF, Ping FY, Xu ZF, Hu JA. Increased levels of CK19 mRNA in oral squamous cell carcinoma tissue detected by relative quantification with real-time polymerase chain reaction. Arch Oral Biol. 2006;51:1112–9.CrossRefPubMedGoogle Scholar
  33. 33.
    Bongers V, Braakhuis BJ, Snow GB. Circulating fragments of cytokeratin 19 in patients with head and neck squamous cell carcinoma. Clin Otolaryngol Allied Sci. 1995;20:479–82.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2016

Authors and Affiliations

  • Rewa Malhotra
    • 1
  • Aadithya B. Urs
    • 1
  • Anita Chakravarti
    • 2
  • Suman Kumar
    • 2
  • V. K. Gupta
    • 3
  • Bhawna Mahajan
    • 3
  1. 1.Department of Oral Pathology and MicrobiologyMaulana Azad Institute of Dental SciencesNew DelhiIndia
  2. 2.Department of MicrobiologyMaulana Azad Medical CollegeNew DelhiIndia
  3. 3.Department of BiochemistryG. B. Pant HospitalNew DelhiIndia

Personalised recommendations